Abstract 2352P
Background
ASCC is a relatively rare malignancy. Several studies reported favourable prognosis in Female to Male patients (pts).Our work aims to identify and quantify sex-based differences in cancer-associated genomic alterations to better inform future precision medicine initiatives and provide insights on potential different survival based on sex.
Methods
A cohort of 1,380 ASCC pts (952 F,428 M) underwent genomic profiling on tissue biopsies using FoundationOne®/FoundationOne®CDx assays, to examine key differences in mutational patterns based on sex and HPV status.
Results
HPV-16 was prevalent in F while HPV-6 in M. PD-L1 expression: over 70% positive (1%), ∼20% high (50%) with similar rates in HPV+ vs HPV- (74.5% vs 63.9%; p=0.16) and sex (F:74% vs M:70.4%; p=0.80). TMB-High (10+mutations/Mb) was found in ∼18% without significant differences by sex (p=0.80); a slightly elevated rate was seen in HPV+ vs HPV- (18.4% vs 14.0%; p=0.16); 34% had PIK3CA alterations (37.1% in HPV+ vs.16.8% in HPV- ; p<.01 with similar rates by sex F:37.1% vs 20.8%; M:37.1% vs 13.3%); in contrast higher prevalence in HPV- vs HPV+ resulted to TP53 (44.9% vs 5.6% p<.01), TERT(31.3% vs 2.7% p<.01), CDNK2A (29% vs 2.9%p<.01), CDNK2B (11.7% vs 1.6% p<.01) and NOTCH1 (14.5% vs 5.1% p<.01); F had higher rates of alterations in PTEN (15.3% vs 8.4%p<.01) ,KMT2D (21% vs 13.1%, p<.01), CBFB (3.3% vs 0.2%; p<.01) and CREBBP (5.4 vs 2.6%; p=0.06),whereas M showed higher rates of alterations in TERT(15.2 vs 3.5% p<.01), TP53 (20.3% vs 7.8% p<.01),CDKN2A (14% vs 3.8%p<.01),CDKN2B (5.4% vs 2.2% p=.02), MYC (4.2% vs 1.6% p=.03) as well as amplifications on 11q13 such as CCND1(7%vs3.2%p=0.02), FGF19 (7%vs3.3%p=0.02), FGF3(7.2%vs3.6%,p=0.02), FGF4 (7% vs 3.5% p=0.02). BRCA1 and BRCA2 mutations were in 5% pts with mild M predominance (7% vs 4%) regardless HPV expression.
Conclusions
The higher incidence of HPV positivity in F compared to M remains the main hypothesis to justify the better prognosis of ASCC in women. A large proportion of PD-L1+ and TMB-High (∼70%), PIK3CA alterations (∼30%) and BRCA1/2 gene alteration (5%) may predict response to possible new therapeutic approaches for pts with ASCC like immunotherapy, targeted tyrosine kinase inhibitors, platinum chemotherapy and PARP inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2346P - Spatial and quantified molecular characterization of high endothelial venule predictive of immunotherapy response
Presenter: Kunheng Du
Session: Poster session 16
2347P - Correlation between second primary cancers and first primary cancers: A systematic review and meta-analysis of 9 million cancer patients
Presenter: Xinyu Wang
Session: Poster session 16
2348P - High-throughput screening reveals GSK1838705A as a potent inhibitor of CAFs-promoted tumor progression in esophageal squamous cell carcinoma
Presenter: hongfang zhang
Session: Poster session 16
2349P - Patterns and frequency of pathogenic germline variants (PGVs) among non-western young male patients with cancer: The Jordanian exploratory cancer genetics (Jo-ECAG) study
Presenter: Hira Bani Hani
Session: Poster session 16
2350P - Single-cell RNA-seq dissecting the initiating liver metastasis cells in various cancers
Presenter: Shu-yue Zheng
Session: Poster session 16
2351P - Whole genome sequencing of AYA patients
Presenter: Paul Roepman
Session: Poster session 16
2353P - Anti-cancer effects of HDAC8 specific inhibitors EC-352H and EC-374H in lymphoma
Presenter: So Young Lee
Session: Poster session 16
2354P - Computational pathology-derived features capture varied epithelial-mesenchymal transition (EMT) states
Presenter: Herbert Levine
Session: Poster session 16
2355P - Carcinoembryonic antigen (CEA) expression in human tumors: A tissue microarray study on 15,413 tumors
Presenter: Kristina Jansen
Session: Poster session 16
2356P - The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC
Presenter: Arianna Marinello
Session: Poster session 16